Biotie in brief
Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease and for which Biotie holds exclusive, global rights. Biotie is actively developing its pipeline assets, including SYN120, a unique potent 5-HT6/5-HT2a dual antagonist for which a Phase 2 study in Alzheimer's diseases is expected to commence recruitment by the end of 2014; nepicastat, a selective inhibitor of dopamine beta hydroxylase which is currently in a Phase 2 study, fully funded by NIDA, for treatment seeking cocaine addicts and for which topline data is expected in the first half of 2015; and BTT-1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 for which a Phase 2 study in primary sclerosing cholangitis, a rare fibrotic disease of the liver, is expected to start recruiting by the end of 2014. Biotie's shares are listed on NASDAQ OMX Helsinki.
(Updated 21 March, 2014)